metformin has been researched along with Hematologic Neoplasms in 6 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess metformin's prophylactic effectiveness of prednisone-induced hyperglycemia among hematological cancer patients." | 9.34 | Metformin's effectiveness in preventing prednisone-induced hyperglycemia in hematological cancers. ( Guantai, EM; Nyamu, DG; Ochola, LA; Weru, IW, 2020) |
| "To assess metformin's prophylactic effectiveness of prednisone-induced hyperglycemia among hematological cancer patients." | 5.34 | Metformin's effectiveness in preventing prednisone-induced hyperglycemia in hematological cancers. ( Guantai, EM; Nyamu, DG; Ochola, LA; Weru, IW, 2020) |
| "Metformin also plays an important role in the treatment of hematologic tumors, especially in leukemia, lymphoma, and multiple myeloma (MM)." | 3.01 | Repurposing Metformin in hematologic tumor: State of art. ( Chen, Y; Hu, M; Jing, L; Ma, T, 2023) |
| "The link between cancer and metabolism has been suggested for a long time but further evidence of this hypothesis came from the recent molecular characterization of the LKB1/AMPK signaling pathway as a tumor suppressor axis." | 2.47 | LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. ( Bouscary, D; Chapuis, N; Green, AS; Lacombe, C; Mayeux, P; Tamburini, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 1 |
| Zhou, F | 1 |
| Guan, J | 1 |
| Zhou, L | 1 |
| Chen, B | 1 |
| Hu, M | 1 |
| Chen, Y | 1 |
| Ma, T | 1 |
| Jing, L | 1 |
| Ochola, LA | 1 |
| Nyamu, DG | 1 |
| Guantai, EM | 1 |
| Weru, IW | 1 |
| Zhou, X | 1 |
| Kuang, Y | 1 |
| Liang, S | 1 |
| Wang, L | 1 |
| Green, AS | 1 |
| Chapuis, N | 1 |
| Lacombe, C | 1 |
| Mayeux, P | 1 |
| Bouscary, D | 1 |
| Tamburini, J | 1 |
| Vakana, E | 1 |
| Platanias, LC | 1 |
4 reviews available for metformin and Hematologic Neoplasms
| Article | Year |
|---|---|
Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review.
Topics: AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Hematologic Neoplasms; Humans; Metformin; | 2023 |
Repurposing Metformin in hematologic tumor: State of art.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Repositioning; Hematologic Neoplasms; Humans; Metformin; Mu | 2023 |
LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Hem | 2011 |
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
Topics: AMP-Activated Protein Kinase Kinases; Genes, abl; Hematologic Neoplasms; Humans; Leukemia; Metformin | 2011 |
1 trial available for metformin and Hematologic Neoplasms
| Article | Year |
|---|---|
Metformin's effectiveness in preventing prednisone-induced hyperglycemia in hematological cancers.
Topics: Adult; Aged; Blood Glucose; Fasting; Female; Hematologic Neoplasms; Humans; Hyperglycemia; Hypoglyce | 2020 |
1 other study available for metformin and Hematologic Neoplasms
| Article | Year |
|---|---|
Metformin inhibits cell proliferation in SKM-1 cells via AMPK-mediated cell cycle arrest.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Proliferation; Cy | 2019 |